While we wait, outside items that may be of interest
posted on
Aug 22, 2017 05:32PM
Advance recommendations for upcoming talks (sent by ESC) include the following three (among others)
5896 Effect of the PCSK9 Inhibitor, Evolocumab, on the Composition of Coronary Atherosclerosis:
Insights from the GLAGOV trial.
Presented by SJ Nicholls
4728 Clinical effects of anacetrapib in people with established vascular disease:
Results of the Randomized EValuation of the Effects of Anacetrapib through Lipid-modification
(HPS3/TIMI55-REVEAL) trial. Presented by M Landray
1151 CANTOS - The Canakinumab Anti-Inflammatory Thrombosis Outcomes Study.
Presented by PM Ridker
On a separate but related note, Here is a link to an article entitled,
"Repairing damaged hearts with self-healing heart cells"
From the Singapore National University
https://www.eurekalert.org/pub_releases/2017-08/nuhs-rdh081817.php